MedPath

Evaluation of Lung Deposition of Aerosol Via HFNC in Healthy Adults

Not Applicable
Conditions
Healthy
Registration Number
NCT02519465
Lead Sponsor
Universidade Federal de Pernambuco
Brief Summary

The aerosol associated with noninvasive ventilation (NIV) and high flow therapy with nasal interface have been employed in an attempt to relieve respiratory distress and optimize the deposition of drugs by inhalation.

Some studies report the effects of NIV association with fogging in healthy subjects, asthmatics and COPD 7.8, but studies evaluating the association between high flow nasal mist interface and therapy are scarce and most are found in vitro and animal models. The objective of this study is to evaluate the deposition of the aerosol scintigraphy using the high flow nasal interface system with vibrating mesh nebulizers using in healthy adults.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
25
Inclusion Criteria
  • The study included healthy individuals of both sexes,
  • between 18 to 65 years,
  • without history of lung disease and forced vital capacity (FVC) or forced expiratory volume in the first second (FEV1) higher or equal to 80% from predicted values,
  • ability to verbal commands understand and
  • willing to provide signed consent to participate in this study.
Exclusion Criteria
  • Participants were excluded if there unable to understand and follow the procedures and were pregnant and unable to tolerate nebulization.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
radioaerosol deposition index into the lungs1 month
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Laboratório de Fisiologia e Fisioterapia Cardiopulmonar

🇧🇷

Recife, Pernambuco, Brazil

Laboratório de Fisiologia e Fisioterapia Cardiopulmonar
🇧🇷Recife, Pernambuco, Brazil
Luciana Alcoforado
Contact
lucalcoforado@yahoo.com.br

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.